Radionuclide imaging in heart failure: Assesing etiology and outcomes and implications for management

Journal of Nuclear Cardiology

Volumn 9, Issue 5 SUPPL., 2002, Pages

  Udelson, James E ^a   Shafer, Colin D ^a   Carrió, Ignasi ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; SPIRONOLACTONE;

CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HEART TRANSPLANTATION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0036765970     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1067/mnc.2002.128461     Document Type: Review

References (109)

1. Konstam MA, Dracup K, Baker DW. Heart failure: evaluation and care of patients with left-ventricular systolic function. Rockville (MD): US Department of Health and Human Services; 1994.
2. Hunt SA, Baker DW, Chin MH. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 2001;38:2101-13.
3. Bounos EP, Mark DB, Pollock BG, et al. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation 1988;78:I-151-7.
4. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983;68:785-95.
5. Bulkley BH, Hutchins GM, Bailey I, et al. Thallium 201 imaging and gated cardiac blood pool scans in patients with ischemic and idiopathic congestive cardiomyopathy. Circulation 1977;55:753-60.
6. Dunn RF, Uren RF, Sadick N, et al. Comparison of thallium 201 scanning in idiopathic dilated cardiomyopathy and severe coronary artery disease. Circulation 1982;66:804-10.
7. Saltissi S, Hockings B, Croft DN, et al. Thallium-201 myocardial imaging in patients with dilated and ischaemic cardiomyopathy. Br Heart J 1981;46:290-5.
8. Eichorn EJ, Kisinski EJ, Lewis SM, et al. Usefulness of dipyridamole-thallium 201 perfusion scanning for distinguishing ischemic from nonischemic cardiomyopathy. Am J Cardiol 1988;62:945-51.
9. Tauberg SG, Orie JE, Bartlett BE, et al. Usefulness of thallium-201 for distinction of ischemic from idiopathic dilated cardiomyopathy. Am J Cardiol 1993;71.
10. Chikamori T, Doi YL, Yonezawa Y, et al. Value of dipyridamole thallium-201 imaging in noninvasive differentiation of idiopathic dilated cardiomyopathy from coronary artery disease with left ventricular dysfunction. Am J Cardiol 1992;69:650-3.
11. Hudson RED. Pathology of cardiomyopathy. Cardiovasc Clin 1972;4:3-59.
12. Cannon ROI, Cunnion RE, Parillo JE, et al. Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest pain. J Am Coll Cardiol 1987;10: 1190-200.
13. Pasternac A, Noble J, Streulens Y, et al. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 1982;65:778-89.
14. Doi YL, Chikamori T, Takata J, et al. Prognostic value of thallium-201 perfusion defects in idiopathic dilated cardiomyopathy. Am J Cardiol 1991;67:188-93.
15. Danias PG, Ahlberg AW, Clark BA, et al. Combined assessment of myocardial perfusion and left ventricular function with exercise Tc99m sestamibi gated SPECT can differentiate between ischemic and nonischemic cardiomyopathy. Am J Cardiol 1998;82:1253-8.
16. Zipes DP. Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation 1990;82:1095-105.
17. Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol 1989;14:1519-26.
18. McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction. Am J Cardiol 1991;67:236-42.
19. Tomoda H, Yoshioka K, Shiina Y, et al. Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina. Am Heart J 1994;128:452-8.
20. Hartikainen J, Mantysaari M, Kuikka J, et al. Extent of cardiac autonomic denervation in relation to angina on exercise test in patients with recent acute myocardial infarction. Am J Cardiol 1994;74:760-3.
21. Hartikainen J, Kuikka J, Mantysaari M, et al. Sympathetic reinnervation after acute myocardial infarction. Am J Cardiol 1996;77:5-9.
22. 123I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med 1999;40:904-10.
23. Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;101:2579-85.
24. Tsutsui H, Ando S, Fukai T, et al. Detection of angina-provoking coronary stenosis by resting iodine 123 metaiodobenzylguanidine scintigraphy in patients with unstable angina pectoris. Am Heart J 1995;129:708-15.
25. Dae MW, Herre JM, O'Connell JW, et al. Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol 1991; 17:1416-23.
26. Minardo JD, Tuli MM, Mock BH, et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988;78:1008-19.
27. Mitrani R, Burt RW, Klein LS, et al. Regional cardiac sympathetic reinnervation following myocardial infarction in humans [abstract]. Circulation 1992;86:I-247.
28. Kammerling JJ, Green FJ, Watanabe AM, et al. Denervation supersensitivity of refractoriness in noninfarcted areas apical to transmural myocardial infarction. Circulation 1987;76:383-93.
29. Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation 1987;75:877-87.
30. Kramer CM, Nicol PD, Rogers WJ, et al. Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction during left ventricular remodeling. J Am Coll Cardiol 1997;30: 1079-85.
31. 123I]MIBG. Q J Nucl Med 1995;39:40-3.
32. Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation 2000;22:2579-85.
33. Dae MW, O'Connell JW, Botvinik E, et al. Acute and chronic effects of transient myocardial ischemia on sympathetic nerve activity, density, and norepinephrine content. Cardiovasc Res 1995;30:270-80.
34. Agostini D, Lecluse E, Belin A, et al. Impact of exercise rehabilitation on cardiac neuronal function in heart failure: an iodine-123 metaiodobenzylguanidine scintigraphy study. Eur J Nucl Med 1998;25:235-41.
35. Estorch M, Flotats A, Serra-Grima R, et al. Influence of exercise rehabilitation on myocardial perfusion and sympathetic heart innervation in ischemic heart disease. Eur J Nucl Med 2000;3:333-9.
36. Bohm M, La Rosee K, Schwinger RH, et al. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995;25:146-53.
37. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
38. Bristow MR, Anderson FL, Port JD, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:1024-39.
39. Bristow MR, Minobe W, Rasmussen R, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992;89:803-15.
40. Ungerer M, Bohm M, Elce JS, et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-63.
41. Rector TS, Olivari MT, Levine TB, et al. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 1987;114:148-52.
42. Rundqvist B, Eisenhofer G, Elam M, et al. Attenuated cardiac sympathetic responsiveness during dynamic exercise in patients with heart failure. Circulation 1997;95:940-5.
43. Kaye DM, Lambert GW, Lefkovits J, et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994;23:570-8.
44. Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63.
45. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-21.
46. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
47. Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988;12:1252-8.
48. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988;78:1192-9.
49. Glowniak JV, Turner FE, Gray LL, et al. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med 1989;30:1182-91.
50. Imamura Y, Ando H, Mitsuoka W, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995;26: 1594-9.
51. Lotze U, Kober A, Kaepplinger S, et al. Cardiac sympathetic activity as measured by myocardial 123-I-metaiodobenzyl-guanidine uptake and heart rate variability in idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:1548-51.
52. 123I-MIBG in the failing human heart. J Nucl Med 1999;40:224-31.
53. 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J 1990;119:1329-37.
54. Taki J, Nakajima K, Bunko H, et al. Whole-body distribution of iodine 123 metaiodobenzylguanidine in hypertrophic cardiomyopathy: significance of its washout from the heart. Eur J Nucl Med 1990;17:264-8.
55. Shimizu M, Sugihara N, Kita Y, et al. Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy. Br Heart J 1992;67:155-60.
56. 123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 1996;76:218-22.
57. Takeishi Y, Atsumi H, Fujiwara S, et al. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997;38:1085-9.
58. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40:217-23.
59. Patel A, Iskandrian AA. MIBG imaging. J Nucl Cardiol 2002; 9:75-94.
60. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
61. Effects of enalapril on mortality in severe congestive heart failure, Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
62. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
63. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
64. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-8.
65. Fukuoka S, Hayashida K, Hirose Y, et al. Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 1997;24:523-9.
66. Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997;133:353-8.
67. 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 1999;81:148-52.
68. 123I-MIBG scintigraphic study. J Nucl Med 2000;41:845-51.
69. Choi JY, Lee KH, Hong KP, et al. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol 2001;8:4-9.
70. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147-52.
71. Szlachcic J, Massie BM, Kramer BL, et al. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol 1985;55:1037-42.
72. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987;59:634-8.
73. Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol 1989;14: 564-72.
74. van den Broek SA, van Veldhuisen DJ, de Graeff PA, et al. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1992;70:359-63.
75. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990;65: 903-8.
76. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
77. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.
78. Momose M, Kobayashi H, Iguchi N. The comparison of parameters of I-123-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathies. Nucl Med Commun 1999;20:529-35.
79. Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-66.
80. Arora R, Ferrick KJ, Nakata T. Utility of I-123 MIBG imaging and heart rate variability analysis as autonomic markers of sudden death. Circulation 2000;102:3512.
81. Lerch H, Wichter T, Schamberger R, et al. Sympathetic myocardial innervation in idiopathic ventricular tachycardia and fibrillation. Eur J Nucl Med 1995;22:805.
82. Schafers M, Lerch H, Wichter T, et al. Cardiac autonomic dysfunction in patients with idiopathic ventricular tachycardia assessed by PET CGP 12177 [abstract]. J Nucl Med 1997;38:1718.
83. Schafers M, Lerch H, Wichter T, et al. cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia. J Am Coll Cardiol 1998;32:181-6.
84. Choudury L, Guzzeti S, Lefroy DC, et al. Myocardial beta-adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart 1996;75:50-5.
85. Lerch H, Bartenstein P, Wichter T, et al. Sympathetic innervation of the left ventricle is impaired in arrhythmogenic right ventricular disease. Eur J Nucl Med 1993;20:207-12.
86. 123I-MIBG scintigraphy. Circulation 1994;89:667-83.
87. Wichter T, Lerch H, Schafers M, et al. Reduction of postsynaptic beta-receptor density in arrhythmogenic right ventricular dysplasia: assessment with positron emission tomography [abstract]. Circulation 1996;94(Suppl I):I-543.
88. De Marco T, Dae M, Yuen MS, et al. Iodine-123 MIBG scintigraphic assessment of the transplanted human heart: evidence for late reinnervation. J Am Coll Cardiol 1995;25: 927-31.
89. Schwaiger M, Hutchins GB, Kalff V. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest 1991;87:1681-90.
90. Dae M, DeMarco T, Botvinick E, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts: implications and clinical studies. J Nucl Med 1992;33:1444-50.
91. 123I-MIBG imaging. J Nucl Med 1999;40:911-6.
92. Kim SJ, Lee JD, Ryu YH, et al. Evaluation of cardiac sympathetic neuronal integrity in diabetic patients using iodine-123 MIBG. Eur J Nucl Med 1996;23:401-6.
93. Morimoto S, Terada K, Keira N, et al. Investigation of the relationship between regression of hypertensive cardiac hypertrophy and improvement of cardiac sympathetic nervous dysfunction using iodine-123-MIBG. Eur J Nucl Med 1996;23:756-61.
94. Morimitsu T, Miyahara Y, Sinboku H, et al. Iodine-123-metaiodobenzylguanidine myocardial imaging in patients with right ventricular pressure overload. J Nucl Med 1996;37:1343-6.
95. 123I-metaiodobenzylguanidine left ventricular imaging. J Nucl Med 2000;7:1127-33.
96. Carrió I, Estorch M, Berná L, et al. Indium-III-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.
97. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
98. Klein H, Auricchio A, Reek S, et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999; 83:91D-97D.
99. Short JH, Darby TD. Sympathetic nervous system blocking agents Derivatives of benzylguanidine. J Med Chem 1967;10:833-40.
100. Dae MW, O'Connell J, Botvinick EH, et al. Scintigraphic assessment of regional cardiac innervation. Circulation 1989; 79:634-44.
101. Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22-31.
102. 123I-iodobenzylguanidine. J Nucl Med 1980;21:349-53.
103. Sisson JC, Wieland DM, Sherman P, et al. Metaiodobenzylguanidine as an index of adrenergic nervous system integrity and function. J Nucl Med 1987;28:1620-4.
104. Sisson JC, Bolgos G, Johnson J. Measuring acute changes in adrenergic nerve activity of the heart in the living animal. Am Heart J 1991;121:1119-23.
105. 123I)iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med 2000;3:302-7.
106. Carrió I. Cardiac neurotransmission imaging. J Nucl Med 2001; 42:1062-76.
107. Gill JS, Hunter GJ, Gane G, et al. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled metaiodobenzylguanidine scintigraphy. Am Heart J 1993;126:390-8.
108. Estorch M, Carrió I, Berná L, et al. Myocardial iodine-labeled metaiodobenzylguanidine uptake relates to age. J Nucl Cardiol 1995;2:126-32.
109. 123I-MIBG by polar map in patients with dilated cardiomyopathy. Nucl Med Commun 1997;3:219-29.